Overview

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
0
Participant gender:
All
Summary
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Cumberland Pharmaceuticals
Theravance Biopharma Antibiotics, Inc.
Treatments:
Methicillin
Telavancin
Vancomycin
Criteria
Inclusion Criteria:

- Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours
of continuous stay in an inpatient acute or chronic care facility or acquired within 7
days after being discharged from a hospitalization of greater than or equal to 3 days
duration.

Exclusion Criteria:

- Received more than 24 hours of potentially effective systemic (IV, IM or PO)
antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.